Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405361 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
A Phase 2 study of Multifocal Motor Neuropathy (MMN), sponsored by argenx.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT05405361 is a Phase 2 study of Multifocal Motor Neuropathy (MMN) that is active but no longer recruiting, run by argenx. The registered enrollment target is 51 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT05405361, a Phase 2 study of Multifocal Motor Neuropathy (MMN), is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety and tolerability, efficacy, immunogenicity, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ARGX-117 Intravenously (IV) in adults with Multifocal Motor Neuropathy (MMN). The trial will include a double-blinded rollover treatment period (DTP), an open-label treatment period (OTP), and a safety follow-up period.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL ARGX-117
Study Locations (20)
Other
- Medizinische Universitat Wien (Medical University of Vienna) - Vienna
- AZ Sint-Lucas - Ghent
- University Health Network - Toronto
- CHU Bordeaux - Groupe Hospitalier Pellegrin - Bordeaux
- Hôpital Roger Salengro (CHU de Lille) - Lille
- CHU de Nice - Nice
- Hôpital de la Pitié Salpétrière - Paris
- Universitätsklinikum Essen - Essen
- Universitatsmedizin Gottingen (UMG) Georg-August-Universitaet - Göttingen
- IRCCS Ospedale San Raffaele S.r.l. - Milan
- Azienda Ospedaliero Universitaria Pisana - Pisa
- Azienda Ospedaliera Sant' Andrea - Rome
- IRCCS Humanitas Research Hospital - Rozzano
- Universitair Medisch Centrum Utrecht - Utrecht
Arizona
- HonorHealth Neurology - Scottsdale
Illinois
- NorthShore University HealthSystem - Glenview
Minnesota
- University of Minnesota - Minneapolis
Ohio
- The Cleveland Clinic Foundation - Cleveland
Pennsylvania
- University of Pennsylvania - Perelman Center for Advanced Medicine - Philadelphia
Texas
- Austin Neuromuscular Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-01-18 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05405361
The ClinicalTrials.gov registry entry for NCT05405361 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multifocal Motor Neuropathy (MMN) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05405361 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT05405361 about?
NCT05405361 is a clinical study titled "A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy". This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety and tolerability, efficacy, immunogenicity, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ARGX-117 Intravenously (IV) in adults with Multifocal Mo...
What is the current status of trial NCT05405361?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2023-01-18. Estimated completion is 2029-09-30.
What conditions does trial NCT05405361 study?
This clinical trial studies the following conditions: Multifocal Motor Neuropathy (MMN).
What interventions are being tested in trial NCT05405361?
The interventions under investigation include: Placebo (OTHER), ARGX-117 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05405361?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05405361 being conducted?
This trial has 20 study locations across Arizona, Illinois, Minnesota, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multifocal Motor Neuropathy (MMN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.